PharmaTalkRadio

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

In this Episode: As clinical trials become more complex, sampling schemes keep pace. That makes proper sample and inventory management so crucial.  Slope's Hope Meely and Kyle Baker shed light on the intricacies and the complexities related to clinical inventory management and sample management. Listeners can learn more about clinical inventory involved for biospecimens, the challenges experienced...

About the Episode: For those of us who work in clinical trials, we know all too well that the majority of sites don't hit recruitment targets, resulting in costly delays and burnout from sites and patients.  Tegan Mead and Julie Mansson, both at Javara, describe how they are applying data and technology to identify the right fit and make sure that sites are set up for success, advising sponsors on...

Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders Joan F. Bachenheimer and Bonnie A. Brescia   The Conference Forum moderates a webcast featuring Joan F. Bachenheimer and Bonnie A. Brescia, the founders of BBK Worldwide, who walk us through the evolution of patient recruitment and engagement, the connection to the women’s and consumer healthcare movement, the need for chan...

Directors, Valerie Bowling and Kate Woda, discuss what to expect at the upcoming 10th annual Mobile Tech in Clinical Trials conference taking place on September 19, 2023 in Boston, MA.

Director, Valerie Bowling, reviews what to expect at the upcoming Clinical Research as a Care Option (CRAACO) conference taking place on May 22-23 at the Sheraton Imperial Hotel in Raleigh-Durham, NC.

In this podcast, you will hear a panel discussion moderated by Paul Jansen from the 2022 PODD Conference regarding the biggest challenges as well as future solutions to vaccine administration and distribution. Panelists include: Jeffrey T Blue, MerckDerek O’Hagan, PhD, GSK To learn more about the PODD Conference, please visit PODDConference.com.  

In this podcast, you will hear a panel discussion moderated by Mark DeStefano, Teva, from the 2022 PODD Conference regarding balancing the level of connected activity with user needs, determining how broadly or specifically to use connectivity and slowly implementing connectivity to provide good user acceptance. Panelists include: Kevin Deane, Phillips-Medisize, a Molex CompanyDavid Harrison, UCBL...

  Why is enhancing the interferon pathway an attractive approach for treating cancer? What are the novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer? What are the translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identif...

In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include: Approach that requires highly specific and efficient multiplex genome editingWhat are some of the potent...

Moderated by: Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics Panelists: Jonathan Fassberg, Vice Chairman of Healthcare Investment Banking, OppenheimerIrina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist SecuritiesGraig Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Bio...

This panel, first recorded at the 2022 IO360° Summit addressed: What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available? Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?What are investors/pharma partners looking for and how does...

In this session, first recorded at the 2022 IO360° Summit, Dr Semenza will talk about how his work is impacting cancer immunotherapy. Dr Semenza’s groundbreaking discovery of hypoxia-inducible factors paves the way for the development of drugs that could kill cancer cells by cutting off the oxygen supply tumors need to grow and improve the response to immunotherapies. Key areas addressed include:...

Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression. This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing. Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understa...

Nouhad Husseini, MBA, SVP, Business Development and Corporate Strategy, Regeneron Pharmaceuticals with Allan Shaw, CFO / Founder & Senior Managing Director, Portage Biotech / Shaw Strategic Capital, LLC Learn more about the IO360 Summit at www.io360summit.com

What is the impact of targeted radiotherapy on the immune system? What are the implications for combination IO?Current approaches and future direction Moderated by: Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen Panelists: Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-PharmaceuticalsJeff Legos, PhD, MBA, EVP, Global Head of Oncology &...

Learn more about the IO360° Summit at www.io360summit.com

In this podcast, you will hear a keynote fireside discussion with Dr Robert Langer, MIT, and Dr Ester Caffarel-Salvador, Chiesi USA, from the 2022 PODD Conference regarding current projects in the Langer Lab, how COVID affected the lab’s dynamics and collaborations, challenges in the drug delivery space, and exciting technologies in the pipeline,  To learn more about the PODD Conference, please vi...

This panel, first recorded at the 2021 Immuno-Oncology 360° Summit, will bring together chinese biotechs to share how they are partnering with additional IO companies to advance cancer treatments for patients. This will include partnering strategies and decision making. To learn more about the IO360° Summit visit, www.io360summit.com

In this session, GSK shares how they delivered on patient and caregiver engagements, especially with communities experiencing the highest COVID burden. They gained insights on study designs, educational pieces and captured patient experiences to enhance HCP/public COVID awareness. GSK will discuss: Value of COVID engagements Novel approaches and mechanisms for finding patients who don’t belong to...

In this session, Janssen shares how they are collaboratively working with patients and sites to advance DCTs and will share engagement methodologies, what they have learned from the perspective of participants and sites, and the direction this has taken them in DCTs. Alyson Gregg, Director Patient Insights, GMA Commercial Operations, Janssen Morgan Wooten, Investigator & Patient Engagement Pro...

Merck’s iLab53 (a modular 39-foot mobile unit) was used to bring clinical research into community settings as an effort to increase clinical trial awareness and engagement. More specifically: How the iLab53 was created and implemented How Merck is continuing to work to help build trust within communities, and provide increased access to clinical research Challenges, learnings and successes to date...

In this session, Sanofi shares how they created and implemented an end-to-end fully integrated patient informed R&D organization that works directly with patients as advisors in 100% of development staged programs from discovery and supporting research pipeline prioritization to registration. Key topics include: Aligning with the patient community’s most pressing needs Gaining insights that es...